BMJ Open
(Jun 2022)
Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial
- Ling Wang,
- Xia Chen,
- Juan Zhao,
- Jiaxi Tang,
- Wanyan Tang,
- Bin Liao,
- Weiqi Nian
Affiliations
- Ling Wang
- Department of Medicine, Michigan State University, East Lansing, Michigan, USA
- Xia Chen
- 1 Department of Anaesthesiology, Shanghai Jiaotong University First People’s Hospital, Shanghai, China
- Juan Zhao
- Department of Social Medicine,School of Health Management, Harbin Medical University, Harbin, Heilongjiang, China
- Jiaxi Tang
- Department of Anesthesiology, Chongqing University Cancer Hospital, Chongqing, China
- Wanyan Tang
- Department of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing, China
- Bin Liao
- Department of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing, China
- Weiqi Nian
- Department of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing, China
- DOI
-
https://doi.org/10.1136/bmjopen-2021-055742
- Journal volume & issue
-
Vol. 12,
no. 6
WeChat QR code
